Evidence map›Paper›PMID 35857073›Full record

Trial reportStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2023

The tumor core boost study: A feasibility study of radical dose escalation to the central part of large tumors with an integrated boost in the palliative treatment setting.

Olaf Wittenstein, Fabian Krause, Mirko Fischer, Justus Domschikowski, Mirko Nitsche, Christoph Henkenberens, Daniel Habermehl, Juergen Dunst

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Olaf WittensteinDepartment of Radiation Oncology, Universitätsklinikum Schleswig-Holstein Campus Kiel, Arnold-Heller-Straße 3, Haus L, 24105, Kiel, Germany. olaf.wittenstein@uksh.de.ORCID 0000-0003-4127-3139
Fabian KrauseDepartment of Radiation Oncology, Universitätsklinikum Schleswig-Holstein Campus Kiel, Arnold-Heller-Straße 3, Haus L, 24105, Kiel, Germany.
Mirko FischerDepartment of Radiotherapy and Special Oncology, Medical School Hannover, Hannover, Germany.
Justus DomschikowskiDepartment of Radiation Oncology, Universitätsklinikum Schleswig-Holstein Campus Kiel, Arnold-Heller-Straße 3, Haus L, 24105, Kiel, Germany.
Mirko NitscheCenter for Radiotherapy and Radio-oncology Bremen and Westerstede, 28239, Bremen, Germany.
Christoph HenkenberensDepartment of Radiotherapy and Special Oncology, Medical School Hannover, Hannover, Germany.
Daniel HabermehlRadprax MVZ, Leimbacher Str. 51a, 42281, Wuppertal, Germany.
Juergen DunstDepartment of Radiation Oncology, Universitätsklinikum Schleswig-Holstein Campus Kiel, Arnold-Heller-Straße 3, Haus L, 24105, Kiel, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeFor patients with large tumors palliative radiotherapy often is the only local treatment option. To prevent toxicity the administered doses are low. Dose escalation to the tumor could be an option to better smyptom control and prolong local control rates. In this prospective study we used a very pragmatic approach with a simultaneously integrated boost (SIB) to an almost geometrically defined tumor core to achieve this. The primary endpoint was to demonstrate feasibility.

methodPatients with solid tumors > 4 cm in diameter of different histologies were eligible in this single arm, prospective, multi-institutional clinical feasibility trial with two treatment concepts: 5 × 5 Gy with an integrated boost to the tumor core of 5 × 10 Gy or 10 × 3 Gy with a boost of 10 × 6 Gy. The objective of dose escalation in this study was to deliver a minimum dose of 150% of the prescribed dose to the gross tumor volume (GTV) tumor core and to reach a maximum of at least 200% in the tumor core.

resultsIn all, 21 patients at three study sites were recruited between January 2019 and November 2020 and were almost evenly spread (9 to 12) between the two concepts. The treated planning target volumes (PTV) averaged 389.42 cm

conclusionsPalliative radiotherapy with SIB to the tumor core seems to be a feasible and well-tolerated treatment concept for large tumors. The applied high doses of up to 50 Gy in 5 fractions (or 60 Gy in 10 fractions) did not cause unexpected side effects in the 42 day follow-up period. Further research is needed for more information on efficacy and long-term toxicity.

Indexed as

NeoplasmsRadiotherapy, Intensity-ModulatedFeasibility StudiesHumansPalliative CareProspective StudiesRadiotherapy DosageRadiotherapy Planning, Computer-AssistedBulky tumorHypofractionationInhomogenous dose distributionPalliative radiotherapyProof of conceptSBRT

Identifiers

PMID35857073
PMCPMC9938025

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.